ArticleNature medicine2026

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.

Kohei Shitara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.